Day: February 28, 2022

The Supervisory Board of AB “Ignitis grupė” (hereinafter – the Group) approved the Strategic Plan 2022–2025 of the Group (hereinafter – the Strategic Plan), which establishes the Group’s ambition to work towards decarbonisation and focus on investments into the Green Generation and Networks (modernisation, resilience  and digitalisation) segments. The Strategic Plan describes the implementation of priorities and directions of the long-term strategy, which was announced in June 2020, for the period of 2022–2025.The Group’s adjusted EBITDA in 2025 is expected to reach EUR 370–410 million and grow by 11–23% compared to 2021. Average adjusted ROCE level for the period of 2022–2025 is expected to reach 5.5–6.5%. The Group’s planned CAPEX for 2022–2025 is EUR 1.7–2.0 billion. EUR 0.8–1.0 billion of the investments will be directed towards...

Ex. date: 28 February 2022Type of corporate action: Rights issueOther information: Reference is made to the bank’s stock exchange releases dated 23 February 2022 and 2 February 2022 for additional information on the rights issue. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act 

AB “Ignitis grupė” (hereinafter – the Group) publishes its Annual report 2021, which is attached to this notice, and announces that the Group’s Adjusted EBITDA grew by 35.3%, compared to 2020, reaching EUR 332.7 million. We surpassed our guidance of EUR 300–310 million by 7.3%, mainly driven by Green Generation, which result increased more than twofold and now makes up one-third of our total result. In 2022, we expect Adjusted EBITDA in the range of EUR 290–335 million. Performance The Group’s Adjusted EBITDA grew in all business segments with Green Generation installed capacity expansion as the main driver, given the higher green electricity generation due to the launch of Pomerania WF (94 MW) and Vilnius CHP WtE unit (19 MWe, 60 MWth), and a full year effect of Kaunas CHP (24 MWe, 70 MWth) launched in August 2020. Increased results of...

Company announcementNo. 08/2022www.orphazyme.comCompany Registration No. 32266355Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announces that CFO Anders Vadsholt will be appointed CEO of Orphazyme effective as of March 1, 2022 and thereby replacing Christophe Bourdon as announced in company announcement no. 3/2022 of January 31, 2022.For additional information, please contact Orphazyme A/S Georges Gemayel, Chairman of the Board of Directors                                Bo Jesper Hansen, Deputy Chairman of the Board of Directors                 Anders Vadsholt, Chief Financial Officer                +45 2898 9055About Orphazyme A/S Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease...

On 25 February 2022, AS Merko Ehitus Eesti, part of AS Merko Ehitus group, signed a contract with Aardekapp OÜ to acquire additional 15% holding (82,500 shares) in Connecto Eesti AS, which designs, builds and maintains electrical, gas and telecommunications networks. The agreement is a continuation of the share acquisition agreements entered into on 2 June 2021. After the acquisition of an additional shareholding, the Merko group owns 50% of Connecto Eesti AS and the latter will become a joint venture between AS Merko Ehitus Eesti and Aardekapp OÜ. The acquisition of a holding as a set of two transactions is not a significant acquisition within the meaning “Requirements for Issuers” of the Tallinn Stock Market rules. AS Merko Ehitus Eesti (merko.ee) is Estonian leading construction company, which offers construction services...

In the fourth quarter, both sales revenue (+13%), adjusted EBITDA (+6%) and profit (+14%) increased. Growth in passenger volume and ferry calls increased revenue in the Passenger harbours segment, which made the biggest contribution to the improvement in the Group’s financial performance. However, profitability indicators improved less than revenue because surging energy prices and some major maintenance and repair works In 2021, the Group’s revenue increased to EUR 110.1 million (+3%) supported by all segments, adjusted EBITDA was EUR 54 million (–8%) and profit amounted to EUR 25.6 million (–10%). Adjusted EBITDA margin decreased by 5.3 percentage points; the volume of investments was EUR 14.7 million (–60%). Due to the impact of the ongoing global COVID-19 crisis, the number of passengers passing through the Group’s harbours in 2021...

Pratteln, Switzerland, February 28, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy. Santhera has entered into an agreement with SEAL Therapeutics, a spin-off company from the Biozentrum of the University of Basel, which will further develop a gene therapy approach intended for the treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2 MD). Santhera will be eligible for payments based on future proceeds of SEAL Therapeutics. Previous license agreements and preclinical collaborations that existed between Santhera and University Basel as well as Rutgers, The State University of New Jersey, have been terminated. SEAL Therapeutics will advance the gene therapy technology building on existing research progress...